In this issue:
- ICI-related diarrhoea/colitis in cancer with GI infections
- Safety of CAR T-cell therapies
- Corticosteroids: impact on CAR T-cell efficacy in large B-cell lymphoma
- Microbiome and immunemediated adverse effects in lung cancer
- Landscape of ICI therapies for advanced lung cancer
- Immune-related adverse events: predictors for ICI efficacy
- Pre-existing autoimmune disease and immune-related adverse events
- Pembrolizumab for metastatic breast cancer with high mutational burden
- Pembrolizumab + ipilimumab after anti-PD-1/L1 failure in melanoma
- Ipilimumab ±anti-PD-1 in anti-PD-(L)1-resistant metastatic melanoma
Download PDF